Pralatrexate showed synergistic cytotoxic activity with several classical cytotoxic agents as well as with targeted EGFR inhibitors in the DU-145 prostate cancer line, and further investigation in clinical trials is warranted. The gene discussed is EGFR; the disease is prostate carcinoma.